Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Leukemia, Myeloid, Acute 18Myeloproliferative Disorders 4Glioma 4Myelodysplastic Syndromes 3Cholangiocarcinoma 3Wilms Tumor 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Leukemia 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Ependymoma 2Chondrosarcoma 2Biliary Tract Neoplasms 2Xanthogranuloma, Juvenile 1Pancreatic Ductal Adenocarcinoma 1Neoplasms, Unknown Primary 1Neoplasm, Residual 1Neoplasm Metastasis 1Lymphoma, Follicular 1IDH1-Mutated Malignancies 1IDH1 Mutation Myeloid Neoplasms 1Histiocytic Sarcoma 1

Interventions

Gemcitabine 32Cisplatin 31durvalumab 15pembrolizumab 14Fluorouracil 13Oxaliplatin 12Leucovorin 12Capecitabine 10Bevacizumab 8lenvatinib 7Nivolumab 7zanidatamab 4Trastuzumab 4S 1 (combination) 4Paclitaxel 4Liquid Biopsy 4Irinotecan 4Carboplatin 4Albumin-Bound Paclitaxel 4tremelimumab 3tislelizumab 3irinotecan sucrosofate 3Injections 3Folfox protocol 3130-nm albumin-bound paclitaxel 3toripalimab 2pertuzumab 2niraparib 2ivosidenib 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × ivosidenib × 1 year × Clear all
NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting
800 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07282262 2025-12-15

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

Peking Union Medical College Hospital

Phase 2 Recruiting
300 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡